Enstilar® is more effective than Dovobet® (calcipotriol/ betamethasone dipropionate) gel at achieving treatment success*
Over the recommended treatment period (4 weeks for Enstilar® and 8 weeks for Dovobet gel [non-scalp]):1
King et al. 2016: Retrospective analysis of the Phase III PSO-ABLE study. PSO-ABLE was a Phase III, randomised, vehicle-controlled, investigator-blinded, multicentre study in patients aged ≥18 years with mild or moderate psoriasis vulgaris (trunk and/or limbs). Treatment success was defined as patients who achieved clear or almost clear skin with at least a two-step improvement in disease severity according to PGA. 36.2% (n=59 /163) of patients using Enstilar® achieved treatment success by week 4 vs 22.5% (n=38/169) using Dovobet gel by week 8 (the recommended treatment period for ‘non-scalp’ areas; p=0.003).1
UK Enstilar® foam and Dovobet® gel cost comparison:3
|Pack size||Treatment||Basic NHS Price|
|60 g||Enstilar® foam||£39.68|
|2 x 60 g|
Are you still using Dovobet® gel?
Optimise your patient’s treatment and advance them to Enstilar®
LEO Pharma Product Licence Indications
Enstilar® is indicated for the topical treatment of psoriasis vulgaris in adults.1 Prescribing information can be found here
Dovobet® gel is indicated for the topical treatment of stable plaque psoriasis vulgaris amenable to topical therapy in adults. Prescribing information can be found here
- King C et al.Poster 237 presented at the 5th Psoriasis International Network Annual Meeting, Paris, France, 5–7 July 2016.
- Koo J et al. J Dermatolog Treat2016; 27(2):120–127.
- BNF formulary. https://www.medicinescomplete.com/mc/bnf/current/. Last accessed August 2019.